Cardiology-HF Flashcards

1
Q

What is the universal definition of heart failure?

A

A clinical syndrome with symptoms/signs due to a structural or functional cardiac abnormality, confirmed by LVEF <50% or elevated natriuretic peptides.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the four classifications of heart failure based on LVEF?

A

HFrEF (≤40%) → Heart Failure with Reduced Ejection Fraction
HFmrEF (41-49%) → Heart Failure with Mildly Reduced EF
HFpEF (≥50%) → Heart Failure with Preserved EF
HFimpEF → LVEF improved from ≤40% by ≥10 points to >40%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Most important compensatory mechanism is
activation of neurohormonal systems. Name 4 mechanisms:

A

– Sympathetic nervous system
– Renin-angiotensin-aldosterone system
– Non-osmotic release of arginine vasopressin
– Natriuretic peptides

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the role of natriuretic peptides in heart failure?

A

They promote natriuresis, vasodilation, and renin suppression, counteracting the SNS and RAAS.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the key symptoms of congestion in heart failure?

A

Dyspnea, orthopnea, paroxysmal nocturnal dyspnea, ankle swelling, pulmonary crackles.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What biomarker levels indicate acute heart failure?

A

BNP >100 pg/mL, >400pg/mL very likely
NT-proBNP >300pg/mL, >450pg/mL very likely

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the four main clinical presentations of acute heart failure?

A

Acute decompensated HF, acute pulmonary edema, cardiogenic shock, isolated right ventricular failure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the initial approach to managing acute heart failure?

A

Lasix (diuretics), Morphine, Nitrates, Oxygen, Position (seated upright)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the first-line diuretic for acute decompensated heart failure?

A

IV furosemide (loop diuretics).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

When are inotropes indicated in AHF?

A

For cardiogenic shock or persistent hypoperfusion despite diuretics and vasodilators.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the contraindications for IABP (intra-aortic balloon pump)?

A

Aortic regurgitation, aortic dissection, severe PAD.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the common causes of acute heart failure?

A

(CHAMPIT)
acute Coronary syndrome
Hypertension emergency
Arrhythmia
Mechanical cause
Pulmonary embolism
Infection
Tamponade

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the most useful imaging modality for diagnosing heart failure?

A

Echocardiography – it assesses LVEF, valvular disease, and wall motion abnormalities.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are typical chest X-ray findings in acute heart failure?

A

Cardiomegaly, pulmonary edema, Kerley B lines, pleural effusion, pulmonary congestion.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the Forrester classification of acute heart failure?

A

Categorizes patients based on cardiac output (CI) and pulmonary capillary wedge pressure (PCWP):

Warm & Dry (I): Normal perfusion, no congestion
Warm & Wet (II): Normal perfusion, congested (most common)
Cold & Dry (III): Hypoperfusion, no congestion
Cold & Wet (IV): Hypoperfusion and congestion (worst prognosis)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the four pillars of guideline-directed medical therapy (GDMT) in HFrEF?

A

ARNI/ACEi/ARB (Sacubitril/Valsartan or Lisinopril)
Beta-blockers (Carvedilol, Metoprolol, Bisoprolol)
MRAs (Spironolactone)
SGLT2 inhibitors (Dapagliflozin, Empagliflozin)

17
Q

What device therapy is recommended for HFrEF patients with LVEF ≤35%?

A

ICD (Implantable Cardioverter Defibrillator) for primary prevention of sudden cardiac death.

18
Q

Treatment goals in acute HF

A

Clinical
- reduce symptoms, clinical signs, congestion
- increase diuresis, oxygenation

Laboratory
- Normalise pH, serium electrolyte, BGM
- Reduce urea and/or creatinine, serum bilirubin

Hemodynamic
- Reduce PCWP <18mmHg
- Increase CO and tissue perfusion

19
Q

What are the recommended tests for chronic heart failure?

A

BNP/Pro-BNP, 12 lead ECG, TTE, CXR, labs: FBC, urea, electrolyte, thyroid, fasting glucose, HbA1C, lipids, Iron status

20
Q

What are the recommended tests to monitor for progress in acute heart failure?

A

– Urea, creatinine, electrolytes
– NT-proBNP
– Arterial blood gases
– Serum lactate level
– Haemoglobin
– Chest Xray
– Others as indicated

21
Q

Tests to evaluate aetiology of heart failure

A

– Echocardiogram
– Coronary angiography (invasive or CT coronary
angiogram)
– Cardiac stress testing– Cardiac MRI
– Endomyocardial biopsy

22
Q

Tests to evaluate pulmonary congestion,
structural heart disease & cardiac dysfunction

A

– ECG (rhythm, structural abnormalities)
– BNP/NT-proBNP levels
– Cardiac troponins
– Echocardiogram
– Cardiac MRI
– Chest Xray (pulmonary congestion, exclude other
pulmonary pathology)
– Lung ultrasound (presence of 3 or more B-lines per
intercostal space a sign of lung interstitial syndrome

23
Q

Tests to evaluate the acutely ill patient:

A

– Full blood counts (anaemia, leucocytosis)
– Urea, creatinine, electrolytes (renal impairment,
hypokalaemia)
– Arterial blood gases (acidosis, hypoxemia, hypercarbia)
– Serum lactate
– Liver function tests (transaminitis, hypoalbuminemia)
– Thyroid function tests
– Iron studies
– Pancultures if high clinical suspicion of infection

24
Q

What is the definition of chronic heart failure (CHF)?

A

A clinical syndrome characterized by impaired cardiac function leading to symptoms such as dyspnea, fatigue, and fluid retention​

25
How is heart failure classified based on symptoms?
NYHA Class I: No symptoms with ordinary physical activity. NYHA Class II: Symptoms with moderate exertion (e.g., walking short distance). NYHA Class III: Symptoms with minimal activity (e.g., bathing). NYHA Class IV: Symptoms at rest​
26
What are the consequences of chronic neurohormonal activation in CHF?
1. Increased aldosterone → Sodium retention→ oedema 2. Increased aldosterone → Fibrosis → increase LV mass →pathologic LV hypertrophy 3. Increased aldosterone →HypoK, HyperMg, fibrosis, Reduced NorA uptake →arrhythmia 4. Increased aldosterone → Reduced arterial compliance, reduced baroreceptor fn, reduced NorA uptake, Increased endothelial dysfunction → ischemia 5. Increased CNS sympathetic outflow → Increased cardiac sympathetic activity in B1,B2,A1 receptors → Myocyte hypertrophy+death, LV dilatation, ischemia, arrhythmias 6. Increased CNS sympathetic outflow → Increased sympathetic activity to kidneys and blood vessels → Vasoconstriction (also A1 activation), sodium retention
27
What drugs should be avoided in CHF?
NSAIDs, thiazolidinediones (glitazones), most calcium channel blockers (except amlodipine), diltiazem, verapamil​
28
What is the only medication proven to reduce hospitalizations in HFpEF?
SGLT2 inhibitors (dapagliflozin, empagliflozin)
29
What non-pharmacologic measures are essential in CHF management?
Daily weight monitoring, sodium/fluid restriction, cardiac rehab, vaccination, advance care planning
30
Other pharmacological treatments indicated in selected patients with NYHA class II-IV heart failure with reduced ejection fraction (LVEF ≤40%)
Ivabradine should be considered in symptomatic patients with LVEF ≤35%, in sinus rhythm and a resting heart rate ≥70 b.p.m Vericiguat may be considered in patients in NYHA class II-IV who have had worsening HF despite treatment with an ACE-I (or ARNI), a beta-blocker and an MRA Digoxin may be considered in patients with symptomatic HFrEF in sinus rhythm despite treatment with an ACE-I (or ARNI), a beta-blocker and an MRA, to reduce the risk of hospitalization (no mortality benefit)
31
Recommendations for anaemia and iron deficiency in patients with heart failure
Iron supplementation should be considered in symptomatic patients with LVEF <45% and iron deficiency, defined as serum ferritin <100 ng/mL or serum ferritin 100–299 ng/mL with TSAT <20%, to alleviate HF symptoms, improve exercise capacity and QOL. Intravenous iron supplementation with ferric carb